SCHEMBL7302739

SCHEMBL7302739

CCCCCn1cc(N2CCNCC2)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.47
ICMT O60725 1/20 0.46
CNR2 P34972 9/20 0.45
CNR1 P21554 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9237227 0.86 CDC25A (0.49) CDC25AICMTCNR2CNR1
SCHEMBL28666665 0.77 DRD2 (0.44) ICMTCNR2
SCHEMBL7136158 0.75 HRH2 (0.49) CDC25AICMTCNR2CNR1
SCHEMBL7712112 0.72 CNR2 (0.59) CDC25AICMTCNR2CNR1
SCHEMBL13131369 0.71 CDC25A (0.72) CDC25AICMTCNR2CNR1
SCHEMBL8363931 0.71 CDC25A (0.59) CDC25AICMTCNR2CNR1
SCHEMBL168724 0.71 CDC25A (0.59) CDC25AICMTCNR2CNR1
SCHEMBL7712109 0.71 CDC25A (0.56) CDC25AICMTCNR2CNR1
SCHEMBL14947367 0.71 CDC25A (0.59) CDC25AICMTCNR2CNR1
SCHEMBL4055511 0.71 HRH2 (0.53) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734384-B1 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS LUNDBECK & CO AS H (DK) 2000-08-09 EP disclosed
EP-0939077-A2 3-Substituted 1-arylindole compounds as 5-HT2 antagonists H. LUNDBECK A/S (DK) 1999-09-01 EP disclosed
EP-0575430-B1 PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ADDICTION TO DRUGS AND SUBSTANCES OF ABUSE LUNDBECK & CO AS H (DK) 1998-08-05 EP disclosed
US-5789404-A CENTRAL NERVOUS SYSTEM DISORDERS AND ANTISEROTONIN AGENTS H. LUNDBECK A/S (DK) 1998-08-04 US disclosed
EP-0392959-B1 Use of sertindole for the treatment of schizophrenia LUNDBECK & CO AS H (DK) 1997-08-20 EP disclosed
EP-0734384-A1 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS H. LUNDBECK A/S (DK) 1996-10-02 EP disclosed
EP-0575429-B1 TREATMENT OF COGNITIVE DISORDERS LUNDBECK & CO AS H (DK) 1995-12-06 EP disclosed
US-5462948-A Treatment of addiction to drugs and substances of abuse H. LUNDBECK A/S (DK) 1995-10-31 US disclosed
US-5444073-A Administering 1-aryl-3-(4-piperidyl)-indole derivatives H. LUNDBECK A/S (DK) 1995-08-22 US disclosed
US-5439922-A Administering dopamine antagonists having reduced side effects H. LUNDBECK A/S (DK) 1995-08-08 US disclosed
WO-1993014758-A1 USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1993-08-05 WO disclosed
WO-1993012790-A1 USE OF ARYLINDOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1993-07-08 WO disclosed
EP-0533824-A1 PIPERIDYL-SUBSTITUTED INDOLES. LUNDBECK & CO AS H (DK) 1993-03-31 EP disclosed
WO-1992015301-A1 TREATMENT OF HYPERTENSION AND PERIPHERAL VASCULAR DISEASES H. LUNDBECK A/S (DK) 1992-09-17 WO disclosed
WO-1992015302-A1 TREATMENT OF ADDICTION TO DRUGS AND SUBSTANCES OF ABUSE H. LUNDBECK A/S (DK) 1992-09-17 WO disclosed
WO-1992015303-A1 TREATMENT OF COGNITIVE DISORDERS H. LUNDBECK A/S (DK) 1992-09-17 WO disclosed
US-5112838-A Treatment of schizophrenia H. LUNDBECK A/S (DK) 1992-05-12 US disclosed
EP-0470039-A2 Novel 3-arylindole and 3-arylindazole derivatives H. LUNDBECK A/S (DK) 1992-02-05 EP disclosed
WO-1992000070-A1 PIPERIDYL-SUBSTITUTED INDOLES H. LUNDBECK A/S (DK) 1992-01-09 WO disclosed
EP-0392959-A2 Use of sertindole for the treatment of schizophrenia H. LUNDBECK A/S (DK) 1990-10-17 EP disclosed